Dateline City:
KENILWORTH, N.J.
KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the National Institute for Health and Care Excellence
(NICE) of the United Kingdom (U.K.) has issued a draft recommendation,
in the form of a Final Appraisal Determination (FAD), recommending
KEYTRUDA (pembrolizumab) as a first-line treatment option
for adults with advanced melanoma.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-236-1130orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more